TY - JOUR
T1 - CAMBO-VIP for advanced diffuse large cell lymphoma (LSG classification) - A long term follow-up study
AU - Okamoto, M.
AU - Maruyama, F.
AU - Tsuzuki, M.
AU - Nomura, T.
AU - Miyazaki, H.
AU - Wakita, M.
AU - Kojima, H.
AU - Sobue, R.
AU - Matsui, T.
AU - Ino, T.
AU - Ezaki, K.
AU - Hirano, M.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1994
Y1 - 1994
N2 - Twenty-two patients with advanced diffuse large cell lymphoma (LSG classification) were treated with the combination chemotherapy of cyclophosphamide, doxorubicin, methotrexate with leucovorin rescue, bleomycin, vincristine, etoposide, ifosfamide and prednisolone (CAMBO-VIP) from Oct. 1987 to Sept. 1989. Eighteen (90%) of 20 evaluable patients achieved complete remission and 2 patients had partial remission. With a median follow-up of 52 mos, 3 patients relapsed (17%), and 2 patients died. The actuarial overall survival and relapse-free survival at 4 years were estimated to be 90% and 83%, respectively. Myelosuppression was severe, but transient. No serious infection was seen, and no platelet transfusion was required. Oral mucositis and liver damage (Grade 3 in WHO grading) was seen in one patient each, but no treatment-related fatalities were observed. CAMBO-VIP is a well tolerated, effective treatment regimen for advanced diffuse large cell lymphoma.
AB - Twenty-two patients with advanced diffuse large cell lymphoma (LSG classification) were treated with the combination chemotherapy of cyclophosphamide, doxorubicin, methotrexate with leucovorin rescue, bleomycin, vincristine, etoposide, ifosfamide and prednisolone (CAMBO-VIP) from Oct. 1987 to Sept. 1989. Eighteen (90%) of 20 evaluable patients achieved complete remission and 2 patients had partial remission. With a median follow-up of 52 mos, 3 patients relapsed (17%), and 2 patients died. The actuarial overall survival and relapse-free survival at 4 years were estimated to be 90% and 83%, respectively. Myelosuppression was severe, but transient. No serious infection was seen, and no platelet transfusion was required. Oral mucositis and liver damage (Grade 3 in WHO grading) was seen in one patient each, but no treatment-related fatalities were observed. CAMBO-VIP is a well tolerated, effective treatment regimen for advanced diffuse large cell lymphoma.
UR - https://www.scopus.com/pages/publications/0028014628
UR - https://www.scopus.com/pages/publications/0028014628#tab=citedBy
M3 - Article
C2 - 7507314
AN - SCOPUS:0028014628
SN - 0385-0684
VL - 21
SP - 67
EP - 73
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 1
ER -